Study of BMS-986012 in Subjects With Small Cell Lung Caner

• Status: Completed
• Trial end date: 2017-08-29
• Target enrollment: 0
• Participant gender: All

Summary

A study to evaluate safety and tolerability of BMS-986012 in patients with small cell lung cancer

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Cisplatin; Etoposide; Etoposide phosphate

Criteria

Inclusion Criteria:

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

• Histological or cytological confirmed small cell lung cancer (SCLC)

• Eastern Cooperative Oncology Group Performance Status 0-1

• at least one measurable lesion that is not amenable to resection.

• Adequate organ function

Exclusion Criteria:

• Symptomatic central nervous system (CNS) metastases

• Grade ≥ 2 peripheral neuropathy

• Uncontrolled or significant cardiac disease

• Active or chronic infection with Human Immunodeficiency Virus(HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV)

Other protocol defined inclusion/exclusion criteria could apply